皮下免疫球蛋白用于患有异常性炎症性肌肉病变的患者:现实世界,单中心体验
Zechen Ma1, Dylan Johnson1, Robert Gniadecki2
1Divsion of Rheumatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Rheumatology (Oxford, England)
|October 5, 2023
概括
皮下免疫球蛋白 (SCIG) 是大多数异常性炎症肌肉病 (IIM) 患者喜欢的,而不是静脉注射免疫球蛋白 (IVIG),而不会恶化疾病活性. 这表明SCIG是IIM维持治疗的可行替代方案.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 神经学 神经学
背景情况:
- 异形性炎症性肌肉病 (IIM) 是一种复杂的自身免疫性疾病,影响骨肌肉.
- 静脉注射免疫球蛋白 (IVIG) 是对耐火IIM的辅助疗法,但具有局限性.
- 皮下免疫球蛋白 (SCIG) 提供了一个替代方案,用于其他炎症和免疫缺陷疾病.
研究的目的:
- 在IIM中评估患者对SCIG和IVIG的满意度和偏好.
- 评估SCIG与IVIG相比在管理IIM方面的有效性.
- 为了确定是否过渡到SCIG影响疾病活动和免疫抑制需求.
主要方法:
- 对20名IIM患者的回顾性审查,他们从IVIG过渡到SCIG超过12个月.
- 通过调查问卷评估患者偏好,比较基于家庭的SCIG与医院的IVIG.
- 使用肌肉炎治疗意向指数 (MITAX) 评估疾病活动,跟踪免疫抑制的变化.
主要成果:
- 显著的大多数 (78.9%) 患者更喜欢SCIG而不是IVIG.
- 在全球疾病活性 (MITAX评分) 或累积类固醇剂量方面没有发现显著差异.
- 药物调整 (免疫抑制升级/降级) 在过渡后是最小的.
结论:
- 在IIM维持治疗中,SCIG是IVIG的首选替代品.
- 在没有增加疾病活性或免疫抑制的情况下,SCIG提供了与IVIG相似的疾病控制.
- 进一步的成本效益研究是有必要的,以支持在IIM使用SCIG.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
154
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
154
Inflammatory Bowel Disease IV: Pharmacological Management
137
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
137
Myasthenia Gravis: Diagnostic Tests
937
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
937
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
178
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
178
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
141
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
141


